Search results
Atossa Therapeutics is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology. Atossa’s current focus is on breast cancer.
Atossa (Old Persian: Utauθa, or Old Iranian: Hutauθa; 550–475 BC) was an Achaemenid empress. She was the daughter of Cyrus the Great , and the wife of Darius the Great . Name [ edit ]
Find the latest Atossa Therapeutics, Inc. (ATOS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Get the latest Atossa Therapeutics Inc (ATOS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines ...
May 15, 2024 · Atossa to Present at the Sidoti Small-Cap Investor Conference. SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024.
4 days ago · Seattle-based Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology. Atossa’s current focus is on breast cancer. View Corporate Presentation.
Mar 31, 2021 · SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announced financial results for the fiscal year ended December 31 ...
4 days ago · Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Ms. Ree
SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a pharmaceutical company specializing in breast cancer therapeutics, has announced significant corporate updates following its 2024 Annual Meeting of Stockholders held on June 27, 2024. The company reported the appointment of a new Chief Financial Officer, the expansion of its stock incentive plan, and the approval of an increase in authorized shares.
